Martindale’s epilepsy oral suspension product approved in 7 European countries
Posted: 27 October 2016 | | No comments yet
Clobazam oral suspension is used principally as an adjunctive therapy for epilepsy with the formulation particularly suitable for children and young adults…
Martindale Pharma has gained the regulatory approval of its clobazam oral suspension product, Epaclob in France, Ireland, Germany and Italy and Silocalm in Denmark, Spain and Iceland following the successful completion of a decentralised procedure (DCP).
Clobazam oral suspension is used principally as an adjunctive therapy for epilepsy with the formulation particularly suitable for children and young adults. Epaclob/Silocalm are approved in two strengths, 5mg/5ml and 10mg/5ml, and will be supplied in packs containing dosing syringes and dosage cups to facilitate accurate dosing and aid adherence to treatment.
Commenting on the approval Michael Harris, CEO of Martindale Pharma, said: “Martindale Pharma is committed to developing and providing high quality innovative products to our customers and to patients in international markets. Already an established product in the UK, this formulation not only allows for better ease of use, especially for paediatrics, but will allow both prescribers and patients access to a much needed safe and cost-effective licensed oral liquid formulation when required.”
